Topographic and anatomical features of the nasolacrimal duct obstruction due to radioiodine treatment
- PMID: 37199817
- DOI: 10.1007/s10792-023-02746-7
Topographic and anatomical features of the nasolacrimal duct obstruction due to radioiodine treatment
Abstract
Purpose: To investigate the topographic and anatomical features of secondary acquired nasolacrimal duct obstruction (SALDO) due to radioiodine therapy.
Methods: Dacryocystography-computed tomography (DCG-CT) scans of the nasolacrimal ducts in 64 cases with SALDO due to radioiodine therapy and in 69 cases with primary acquired nasolacrimal duct obstruction (PANDO) were studied. The anatomical site of obstruction was located, and morphometric characteristics of the nasolacrimal ducts were calculated: volume, length, and average sectional area. The statistical analysis was performed using the t-criterion, ROC analysis, and the odds ratio (OR).
Results: The mean nasolacrimal section area was 10.7 ± 0.8 mm2 in patients with PANDO and 13.2 ± 0.9 mm2 in patients with SALDO due to radioiodine therapy (p = 0.039); the AUC value in ROC analysis for this parameter was 0.607 (p = 0.037). The development of "proximal" obstruction including lacrimal canaliculi obstruction and obstruction at the site of the lacrimal sac was 4.076 times more likely (CI: 1.967-8.443) in patients with PANDO than in patients with SALDO due to radioactive iodine exposure.
Conclusions: By comparing CT scans of the nasolacrimal ducts, we observed that in SALDO obstruction due to radioactive iodine therapy is predominantly "distal," while in PANDO it is more often "proximal." The development of obstruction within SALDO is followed by more pronounced suprastenotic ectasia.
Keywords: CT; Dacryocystography; Radioiodine; Secondary acquired nasolacrimal duct obstruction.
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
Computed Tomography - Dacryocystography Guided Management of Traumatic Secondary Acquired Lacrimal Duct Obstruction: SALDO Update Study (SUP) - Paper V.Curr Eye Res. 2025 Apr;50(4):454-459. doi: 10.1080/02713683.2025.2452914. Epub 2025 Jan 20. Curr Eye Res. 2025. PMID: 39831386
-
Dependence of radioactive iodine-131 capture by the lacrimal ducts on the tear production level.Indian J Ophthalmol. 2023 May;71(5):1828-1832. doi: 10.4103/IJO.IJO_2780_22. Indian J Ophthalmol. 2023. PMID: 37203037 Free PMC article.
-
Dynamic viscosity of the wall of the lacrimal sac in disorders of the patency of the lacrimal ducts.Int Ophthalmol. 2024 Apr 8;44(1):171. doi: 10.1007/s10792-024-03112-x. Int Ophthalmol. 2024. PMID: 38587686
-
Etiopathogenesis of primary acquired nasolacrimal duct obstruction (PANDO).Prog Retin Eye Res. 2023 Sep;96:101193. doi: 10.1016/j.preteyeres.2023.101193. Epub 2023 Jul 1. Prog Retin Eye Res. 2023. PMID: 37394093 Review.
-
Clinically suspected primary acquired nasolacrimal duct obstruction: clinicopathologic review of 150 patients.Ophthalmology. 1997 Nov;104(11):1882-6. doi: 10.1016/s0161-6420(97)30012-8. Ophthalmology. 1997. PMID: 9373121 Review.
Cited by
-
Update on lacrimal apparatus dysfunction associated with differentiated thyroid cancer after I-131 therapy.Int Ophthalmol. 2024 Jun 23;44(1):257. doi: 10.1007/s10792-024-03192-9. Int Ophthalmol. 2024. PMID: 38909080 Review.
-
Nasolacrimal duct rhinostomy for low-level nasolacrimal duct obstruction:long-term outcomes and surgical selection paradigm.Eur Arch Otorhinolaryngol. 2024 Nov;281(11):5783-5792. doi: 10.1007/s00405-024-08797-5. Epub 2024 Aug 6. Eur Arch Otorhinolaryngol. 2024. PMID: 39107549
-
Ocular Surface Fluid: More than a Matrix.Toxics. 2024 Jul 16;12(7):513. doi: 10.3390/toxics12070513. Toxics. 2024. PMID: 39058165 Free PMC article. Review.
-
Absorption of Toxicants from the Ocular Surface: Potential Applications in Toxicology.Biomedicines. 2025 Mar 6;13(3):645. doi: 10.3390/biomedicines13030645. Biomedicines. 2025. PMID: 40149621 Free PMC article. Review.
References
Reference Lists
-
- Avdagic E, Phelps PO (2020) Nasolacrimal duct obstruction as an important cause of epiphora. Dis Mon 66:101043. https://doi.org/10.1016/j.disamonth.2020.101043 - DOI - PubMed
-
- Mills DM, Meyer DR (2006) Acquired nasolacrimal duct obstruction. Otolaryngol Clin North Am 39(979–999):vii. https://doi.org/10.1016/j.otc.2006.07.002 - DOI - PubMed
-
- Thompson CJ (2001) Review of the diagnosis and management of acquired nasolacrimal duct obstruction. Optometry 72:103–111 - PubMed
-
- Pinto IT, Paul L, Grande C (1998) Nasolacrimal polyurethane stent: complications with CT correlation. Cardiovasc Intervent Radiol 21:450–453. https://doi.org/10.1007/s002709900302 - DOI - PubMed
-
- Yang MK, Sa HS, Kim N, Kim JH, Choung H, Khwarg SI (2022) Bony nasolacrimal duct size and outcomes of nasolacrimal silicone intubation for incomplete primary acquired nasolacrimal duct obstruction. PLoS One 17:0266040. https://doi.org/10.1371/journal.pone.0266040 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical